A LinkedIn post from Saluda Medical highlights clinical experience with its Evoke System for spinal cord stimulation in chronic pain management. The post cites comments from Dr. Johnathan Goree, described as a paid consultant, suggesting his Evoke patients require less frequent device reprogramming than with other systems.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, study participants reportedly averaged about one reprogramming visit after 12 months, while real‑world patients were said to reach zero reprogramming visits by 12 months. These data were presented at ASPN 2025 in a session titled “Minimal SCS Reprogramming in Study and Real-World Clinical Practice Settings Using the Evoke System.”
For investors, the post implies potential workflow and cost efficiencies for clinics if reduced reprogramming needs are confirmed more broadly. Lower maintenance burden could strengthen the Evoke System’s value proposition versus competing spinal cord stimulation platforms, potentially aiding adoption and supporting pricing power.
However, the information presented is limited in detail and comes from a consultant-sponsored perspective, with individual results noted as variable. Investors may wish to see peer-reviewed data, larger real‑world datasets, and payer responses before drawing conclusions about long-term revenue impact or competitive differentiation for Saluda Medical.